DSIP Dosage Calculator

The presets in our calculator reflect the dosing parameters most frequently utilized in in vivo sleep architecture and neuroendocrine stress models.

• Low (0.1mg / 100mcg): Often utilized in baseline sleep architecture models or studies tracking mild electroencephalogram (EEG) changes and baseline circadian rhythmicity.¹
• Mid (0.25mg / 250mcg): The standard median dosage in experimental literature, frequently cited in protocols observing substantial shifts toward slow-wave (delta) sleep and modulation of the stress axis (e.g., corticosterone reduction).²
• High (0.5mg / 500mcg): The upper threshold typically used in acute study phases focusing on severe sleep disturbances, withdrawal simulation models, or subjects requiring a higher systemic exposure to achieve significant neuroendocrine modulation.³
  

In experimental protocols, DSIP is most commonly administered once daily shortly before sleep. To accurately model natural circadian rhythmicity and promote slow-wave sleep onset, research universally stipulates administration immediately prior to the dark cycle (or the subject’s intended sleep period).

Research literature documents several administration routes, largely dictated by the specific objective of the neuro-monitoring:

• Subcutaneous (SubQ): The benchmark route for systemic research. SubQ administration has successfully demonstrated the peptide’s unique ability to cross the blood-brain barrier (BBB) intact, influencing central nervous system (CNS) parameters like EEG delta rhythm and HPA-axis stress responses.⁴
• Intravenous (IV): Frequently utilized in acute, highly controlled laboratory settings to observe immediate shifts in heart rate variability and rapid EEG alterations, though SubQ provides a more practical absorption curve for behavioral models.³
  

DSIP research generally follows acute timelines, focusing on immediate electrophysiological and hormonal shifts:

• Acute Sleep Models: 1 to 7 days is the standard timeline for observing immediate changes in EEG patterns, specifically the increase in deep slow-wave sleep (DSWS) and the reduction of sleep onset latency.⁴
• Sub-Acute Stress Models: 2 to 4 weeks when tracking the peptide’s cumulative effect on hormonal normalization, such as the blunting of corticotropin-releasing factor (CRF) and cortisol/corticosterone in chronic stress environments.¹
  

While in vivo animal models demonstrate DSIP’s profound ability to cross the blood-brain barrier, promote slow-wave sleep, and modulate the physiological stress response, large-scale, peer-reviewed human clinical trials are currently lacking. DSIP is not approved by the FDA for treating insomnia, sleep disorders, anxiety, or withdrawal syndromes in humans. All data provided is strictly for educational context, and all compounds are restricted to Research Use Only (RUO).

1. Graf MV, Kastin AJ, Coy DH, Fischman AJ. Delta-sleep-inducing peptide reduces CRF-induced corticosterone release. Neuroendocrinology. 1985;41(4):353-356. https://pubmed.ncbi.nlm.nih.gov/2995861/
2. Graf MV, Kastin AJ. Delta-sleep-inducing peptide (DSIP): a review. Neurosci Biobehav Rev. 1984;8(1):83-93. https://pubmed.ncbi.nlm.nih.gov/6145137/
3. Schoenenberger GA. Characterization, properties and multivariate functions of delta-sleep-inducing peptide (DSIP). Eur Neurol. 1984;23(5):321-345. https://pubmed.ncbi.nlm.nih.gov/6548966/
4. Susić V. The effect of subcutaneous administration of delta sleep-inducing peptide (DSIP) on some parameters of sleep in the cat. Physiol Behav. 1987;40(5):569-572. https://pubmed.ncbi.nlm.nih.gov/3671519/